Table 2. Studies combining thermal ablation and immunotherapy that are currently registered at clinicaltrials.gov.

Identifier	Title	Primary endpoint
NCT04339218 (111)	Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients with Metastatic Lung Adenocarcinoma (CRYOMUNE)	1-year overall survival
NCT04201990 (112)	Cryoablation Combined with Camrelizumab and Apatinib for Multiprimary Lung Cancer (CCA-MPLC)	Safety
NCT04102982 (113)	Microwave Ablation in Combination with Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer (MWA in NSCLC)	Overall survival
NCT03769129 (114)	Evaluating the Safety and Efficacy of Pembrolizumab Combined with MWA for Advanced NSCLC	Overall survival
NCT03290677 (115)	Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumour in Patients with Metastatic Lung Cancer and Metastatic Melanoma Receiving Post-Progression Immune Checkpoint Inhibitor Therapy	Cumulative incidence of treatment related serious adverse events